Latest Breaking News On - Corneal endothelial - Page 2 : comparemela.com

Arctic Vision announces exclusive licensing agreement with ActualEyes News provided by Share this article Share this article To develop and commercialize cell therapy to potentially replace corneal endothelial keratoplasty in Greater China and South Korea Arctic Vision to partner with ActualEyes to introduce novel approach of using cultured corneal endothelial cells to treat corneal endothelial dysfunction and potentially replace corneal endothelial keratoplasty. Under the terms of the agreement, the deal is worth up to more than USD 35 million, including upfront, regulatory milestone payments, and tiered royalties. SHANGHAI, May 14, 2021 /PRNewswire/ Arctic Vision, a clinical stage biotech company focused on innovative ophthalmology therapies for pan-ocular diseases, and ActualEyes, a clinical stage Japanese biotech company committed to the research and development of cell therapy for corneal endothelial diseases, today jointly announced an exclusive licensing agreement for

Shigeru koizumiIku sugiokaKohsaku imaiNaoki okumuraNoriko koizumiNaoki okumura at doshisha universityNew england journalBoard directorArctic visionChief executive officerCultured cellsNew englandFive year follow upFirst eleven cases undergoing injectionCultured corneal endothelial cellsCorneal endothelial